NO313142B1 - Endothelin-antagonister: N-[[2'-[[(4,5-dimetyl-3- isoksazolyl)amino]sulfonyl]-4-(2-oksazolyl[[1,1'-bifenyl]-2-yl]metyl]-N,3,3-trimetylbutanamid og N-(4,5-dimetyl-3-isoksazolyl)-2'-[(3,3-dimetyl-2-okso-1-pyrrolidinyl)metyl]-4'-(2-oksazolyl)[1,1'-b - Google Patents
Endothelin-antagonister: N-[[2'-[[(4,5-dimetyl-3- isoksazolyl)amino]sulfonyl]-4-(2-oksazolyl[[1,1'-bifenyl]-2-yl]metyl]-N,3,3-trimetylbutanamid og N-(4,5-dimetyl-3-isoksazolyl)-2'-[(3,3-dimetyl-2-okso-1-pyrrolidinyl)metyl]-4'-(2-oksazolyl)[1,1'-b Download PDFInfo
- Publication number
- NO313142B1 NO313142B1 NO19993691A NO993691A NO313142B1 NO 313142 B1 NO313142 B1 NO 313142B1 NO 19993691 A NO19993691 A NO 19993691A NO 993691 A NO993691 A NO 993691A NO 313142 B1 NO313142 B1 NO 313142B1
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- compound according
- dimethyl
- preparation
- isoxazolyl
- Prior art date
Links
- 102000002045 Endothelin Human genes 0.000 title claims abstract description 24
- 108050009340 Endothelin Proteins 0.000 title claims abstract description 24
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title claims abstract description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title claims abstract description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 title claims abstract description 7
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title claims description 10
- 235000010290 biphenyl Nutrition 0.000 title claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims description 5
- -1 4,5-Dimethyl-3-isoxazolyl Chemical group 0.000 title abstract description 17
- 239000005557 antagonist Substances 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 119
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims description 88
- 239000000203 mixture Substances 0.000 claims description 34
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 24
- 208000035475 disorder Diseases 0.000 claims description 21
- 102000003729 Neprilysin Human genes 0.000 claims description 12
- 108090000028 Neprilysin Proteins 0.000 claims description 12
- 206010020772 Hypertension Diseases 0.000 claims description 11
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 11
- JNAFKCJWVUJAQU-UHFFFAOYSA-N n-(4,5-dimethyl-1,2-oxazol-3-yl)-2-[2-[(3,3-dimethyl-2-oxopyrrolidin-1-yl)methyl]-4-(1,3-oxazol-2-yl)phenyl]benzenesulfonamide Chemical group CC1=C(C)ON=C1NS(=O)(=O)C1=CC=CC=C1C1=CC=C(C=2OC=CN=2)C=C1CN1C(=O)C(C)(C)CC1 JNAFKCJWVUJAQU-UHFFFAOYSA-N 0.000 claims description 10
- ORJRYNKVKJAJPY-UHFFFAOYSA-N n-[[2-[2-[(4,5-dimethyl-1,2-oxazol-3-yl)sulfamoyl]phenyl]-5-(1,3-oxazol-2-yl)phenyl]methyl]-n,3,3-trimethylbutanamide Chemical group CC(C)(C)CC(=O)N(C)CC1=CC(C=2OC=CN=2)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C ORJRYNKVKJAJPY-UHFFFAOYSA-N 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 8
- 230000001434 glomerular Effects 0.000 claims description 8
- 229940044551 receptor antagonist Drugs 0.000 claims description 8
- 239000002464 receptor antagonist Substances 0.000 claims description 8
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 7
- 239000005541 ACE inhibitor Substances 0.000 claims description 6
- 102000005862 Angiotensin II Human genes 0.000 claims description 6
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 6
- 208000037487 Endotoxemia Diseases 0.000 claims description 6
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 6
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 6
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 6
- 229950006323 angiotensin ii Drugs 0.000 claims description 6
- 229940097217 cardiac glycoside Drugs 0.000 claims description 6
- 239000002368 cardiac glycoside Substances 0.000 claims description 6
- 239000002934 diuretic Substances 0.000 claims description 6
- 210000003904 glomerular cell Anatomy 0.000 claims description 6
- 210000003584 mesangial cell Anatomy 0.000 claims description 6
- 206010027599 migraine Diseases 0.000 claims description 6
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 239000002461 renin inhibitor Substances 0.000 claims description 6
- 229940086526 renin-inhibitors Drugs 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 6
- 229930002534 steroid glycoside Natural products 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 229940097420 Diuretic Drugs 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000001882 diuretic effect Effects 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- DIQWXFONCLXJHX-UHFFFAOYSA-N n-(4,5-dimethyl-1,2-oxazol-3-yl)-2-[2-(hydroxymethyl)-4-(1,3-oxazol-2-yl)phenyl]-n-(2-methoxyethoxymethyl)benzenesulfonamide Chemical group C=1C=CC=C(C=2C(=CC(=CC=2)C=2OC=CN=2)CO)C=1S(=O)(=O)N(COCCOC)C1=NOC(C)=C1C DIQWXFONCLXJHX-UHFFFAOYSA-N 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- XIQCUSMDJBCCFP-UHFFFAOYSA-N 2-[2-(bromomethyl)-4-(1,3-oxazol-2-yl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)-n-(2-methoxyethoxymethyl)benzenesulfonamide Chemical group C=1C=CC=C(C=2C(=CC(=CC=2)C=2OC=CN=2)CBr)C=1S(=O)(=O)N(COCCOC)C1=NOC(C)=C1C XIQCUSMDJBCCFP-UHFFFAOYSA-N 0.000 claims description 2
- KWINXKCFRTZGNF-UHFFFAOYSA-N n-(4,5-dimethyl-1,2-oxazol-3-yl)-2-[2-(methylaminomethyl)-4-(1,3-oxazol-2-yl)phenyl]benzenesulfonamide Chemical group CNCC1=CC(C=2OC=CN=2)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C KWINXKCFRTZGNF-UHFFFAOYSA-N 0.000 claims description 2
- IOMNOPOKADIXTG-UHFFFAOYSA-N n-(4,5-dimethyl-1,2-oxazol-3-yl)-2-[2-[(3,3-dimethyl-2-oxopyrrolidin-1-yl)methyl]-4-(1,3-oxazol-2-yl)phenyl]-n-(2-methoxyethoxymethyl)benzenesulfonamide Chemical group C=1C=CC=C(C=2C(=CC(=CC=2)C=2OC=CN=2)CN2C(C(C)(C)CC2)=O)C=1S(=O)(=O)N(COCCOC)C1=NOC(C)=C1C IOMNOPOKADIXTG-UHFFFAOYSA-N 0.000 claims description 2
- DCUDXCKZPAFHQS-UHFFFAOYSA-N n-(4,5-dimethyl-1,2-oxazol-3-yl)-2-[2-formyl-4-(1,3-oxazol-2-yl)phenyl]-n-(2-methoxyethoxymethyl)benzenesulfonamide Chemical group C=1C=CC=C(C=2C(=CC(=CC=2)C=2OC=CN=2)C=O)C=1S(=O)(=O)N(COCCOC)C1=NOC(C)=C1C DCUDXCKZPAFHQS-UHFFFAOYSA-N 0.000 claims description 2
- DZDZLHPZRHZBTJ-UHFFFAOYSA-N n-(4,5-dimethyl-1,2-oxazol-3-yl)-2-[2-formyl-4-(1,3-oxazol-2-yl)phenyl]benzenesulfonamide Chemical group CC1=C(C)ON=C1NS(=O)(=O)C1=CC=CC=C1C1=CC=C(C=2OC=CN=2)C=C1C=O DZDZLHPZRHZBTJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 9
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000000047 product Substances 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- 239000000243 solution Substances 0.000 description 16
- 239000000460 chlorine Substances 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000002503 metabolic effect Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000036584 pressor response Effects 0.000 description 4
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 206010029155 Nephropathy toxic Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002308 endothelin receptor antagonist Substances 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 230000007694 nephrotoxicity Effects 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- 125000000962 organic group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 108010058207 Anistreplase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UWTINOJTWXLCEI-UHFFFAOYSA-N [2-[(4,5-dimethyl-1,2-oxazol-3-yl)-(2-methoxyethoxymethyl)sulfamoyl]phenyl]boronic acid Chemical compound C=1C=CC=C(B(O)O)C=1S(=O)(=O)N(COCCOC)C1=NOC(C)=C1C UWTINOJTWXLCEI-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 2
- 229960003065 bosentan Drugs 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- NVXFXLSOGLFXKQ-JMSVASOKSA-N (2s)-1-[(2r,4r)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)[C@H](C)C[C@@H](C)C(=O)OCC)[C@H](C(O)=O)CC2=C1 NVXFXLSOGLFXKQ-JMSVASOKSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 1
- IFYLTXNCFVRALQ-UHFFFAOYSA-N 1-[6-amino-2-[hydroxy(4-phenylbutyl)phosphoryl]oxyhexanoyl]pyrrolidine-2-carboxylic acid Chemical compound C1CCC(C(O)=O)N1C(=O)C(CCCCN)OP(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-UHFFFAOYSA-N 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- ZVOZUMCLFHQEPJ-UHFFFAOYSA-N 2-bromo-5-(1,3-oxazol-2-yl)benzaldehyde Chemical compound C1=C(C=O)C(Br)=CC=C1C1=NC=CO1 ZVOZUMCLFHQEPJ-UHFFFAOYSA-N 0.000 description 1
- AEHZMTLXZJYRCA-UHFFFAOYSA-N 2-bromo-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound CC1=C(C)ON=C1NS(=O)(=O)C1=CC=CC=C1Br AEHZMTLXZJYRCA-UHFFFAOYSA-N 0.000 description 1
- VFPWGZNNRSQPBT-UHFFFAOYSA-N 2-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1Br VFPWGZNNRSQPBT-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 1
- OKMACEDCNMXXEX-UHFFFAOYSA-N 3,3-dimethyl-2-oxopyrrolidine-1-carboxylic acid Chemical compound CC1(C)CCN(C(O)=O)C1=O OKMACEDCNMXXEX-UHFFFAOYSA-N 0.000 description 1
- BUTKIHRNYUEGKB-UHFFFAOYSA-N 3,3-dimethylbutanoyl chloride Chemical compound CC(C)(C)CC(Cl)=O BUTKIHRNYUEGKB-UHFFFAOYSA-N 0.000 description 1
- OKVZHGPFRXBQHI-UHFFFAOYSA-N 4,5-dimethyl-1,2-oxazol-3-amine;hydrochloride Chemical compound Cl.CC=1ON=C(N)C=1C OKVZHGPFRXBQHI-UHFFFAOYSA-N 0.000 description 1
- FBYVPNQCVJSPPQ-UHFFFAOYSA-N 4-amino-2,2-dimethylbutanoic acid;hydrochloride Chemical compound Cl.OC(=O)C(C)(C)CCN FBYVPNQCVJSPPQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000026005 Central nervous system vascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000007836 Chlorogalum pomeridianum Nutrition 0.000 description 1
- 240000006670 Chlorogalum pomeridianum Species 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010013012 Dilatation ventricular Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 101100050098 Enterobacteria phage T4 y05Q gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 206010047370 Vesicoureteric reflux Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000009895 amole Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003440 anti-fibrillation Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- XORXDJBDZJBCOC-UHFFFAOYSA-N azanium;acetonitrile;acetate Chemical compound [NH4+].CC#N.CC([O-])=O XORXDJBDZJBCOC-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000008148 cardioplegic solution Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- IIJREXIVDSIOFR-UHFFFAOYSA-N dichloromethane;heptane Chemical compound ClCCl.CCCCCCC IIJREXIVDSIOFR-UHFFFAOYSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960003028 flumethiazide Drugs 0.000 description 1
- RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000023569 ischemic bowel disease Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- NUJMTBRJXROCOI-UHFFFAOYSA-N n,3,3-trimethylbutanamide Chemical compound CNC(=O)CC(C)(C)C NUJMTBRJXROCOI-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229950008492 pentopril Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 108010072906 phosphoramidon Proteins 0.000 description 1
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940073095 questran Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 1
- 229960002578 sitaxentan Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- PLQFNMSPAPPXFW-UHFFFAOYSA-N tert-butyl n-(4,5-dimethyl-1,2-oxazol-3-yl)carbamate Chemical compound CC=1ON=C(NC(=O)OC(C)(C)C)C=1C PLQFNMSPAPPXFW-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- XWNXEWLCHSLQOI-UHFFFAOYSA-K trisodium;triacetate Chemical compound [Na+].[Na+].[Na+].CC([O-])=O.CC([O-])=O.CC([O-])=O XWNXEWLCHSLQOI-UHFFFAOYSA-K 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 201000008618 vesicoureteral reflux Diseases 0.000 description 1
- 208000031355 vesicoureteral reflux 1 Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3583297P | 1997-01-30 | 1997-01-30 | |
PCT/US1998/001490 WO1998033780A1 (fr) | 1997-01-30 | 1998-01-26 | Antagonistes de l'endotheline: n-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-n,3,3-trimethylbutanamide et n-(4,5-dimethyl-3-isoxazolyl)-2'-[3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide et leurs sels |
Publications (3)
Publication Number | Publication Date |
---|---|
NO993691D0 NO993691D0 (no) | 1999-07-29 |
NO993691L NO993691L (no) | 1999-07-29 |
NO313142B1 true NO313142B1 (no) | 2002-08-19 |
Family
ID=21885049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19993691A NO313142B1 (no) | 1997-01-30 | 1999-07-29 | Endothelin-antagonister: N-[[2'-[[(4,5-dimetyl-3- isoksazolyl)amino]sulfonyl]-4-(2-oksazolyl[[1,1'-bifenyl]-2-yl]metyl]-N,3,3-trimetylbutanamid og N-(4,5-dimetyl-3-isoksazolyl)-2'-[(3,3-dimetyl-2-okso-1-pyrrolidinyl)metyl]-4'-(2-oksazolyl)[1,1'-b |
Country Status (22)
Country | Link |
---|---|
US (1) | US6043265A (fr) |
EP (1) | EP0996618B1 (fr) |
JP (1) | JP2002513397A (fr) |
KR (1) | KR20000070584A (fr) |
CN (1) | CN1117738C (fr) |
AR (1) | AR015358A1 (fr) |
AT (1) | ATE254115T1 (fr) |
AU (1) | AU730111B2 (fr) |
BR (1) | BR9807098A (fr) |
CA (1) | CA2279178A1 (fr) |
CZ (1) | CZ236299A3 (fr) |
DE (1) | DE69819729T2 (fr) |
ES (1) | ES2205451T3 (fr) |
HU (1) | HUP0001310A3 (fr) |
IL (1) | IL130622A (fr) |
NO (1) | NO313142B1 (fr) |
NZ (1) | NZ336380A (fr) |
PL (1) | PL334773A1 (fr) |
RU (1) | RU2183632C2 (fr) |
TW (1) | TW536540B (fr) |
WO (1) | WO1998033780A1 (fr) |
ZA (1) | ZA98759B (fr) |
Families Citing this family (215)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
HU227183B1 (en) | 1997-04-28 | 2010-09-28 | Encysive Pharmaceuticals Inc | Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders |
US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
JP5187991B2 (ja) | 1997-10-17 | 2013-04-24 | アーク・セラピューティックス・リミテッド | レニン−アンジオテンシン系の阻害剤の使用 |
AU1591699A (en) * | 1998-03-17 | 1999-10-11 | Warner-Lambert Company | Statin-matrix metalloproteinase inhibitor combinations |
AU767456B2 (en) | 1998-07-06 | 2003-11-13 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
AU2092601A (en) * | 1999-12-15 | 2001-06-25 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
CA2395684C (fr) | 1999-12-31 | 2012-01-03 | Texas Biotechnology Corporation | Sulfonamides et leurs derives modulant l'activite de l'endotheline |
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7645898B2 (en) * | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
US6639082B2 (en) * | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
AU2002241736A1 (en) * | 2000-12-21 | 2002-07-01 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
WO2002083130A1 (fr) * | 2001-04-16 | 2002-10-24 | Bristol-Myers Squibb Company | Enantiomeres de n-[[2'-[[(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-n,3,3-trimethylbutanamide |
CA2726702A1 (fr) | 2001-09-21 | 2003-04-03 | Bristol-Myers Squibb Company | Composes contenant du lactame et leurs derives en tant qu'inhibiteurs du facteur xa |
KR20040054729A (ko) * | 2001-10-18 | 2004-06-25 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도 |
US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
US7772433B2 (en) * | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
US7435824B2 (en) * | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
US7405234B2 (en) * | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
AU2003276648A1 (en) * | 2002-06-17 | 2003-12-31 | Bristol-Myers Squibb Company | Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase |
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
AU2003270357A1 (en) * | 2002-09-06 | 2004-03-29 | Microbia, Inc. | Inhibitors of fungal invasion |
ES2344057T3 (es) * | 2002-10-23 | 2010-08-17 | Bristol-Myers Squibb Company | Inhibidores de la dipeptidil peptidasa iv basados en nitrilos de glicina. |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
EP1567487A4 (fr) * | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
TW200504021A (en) * | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
JP2006516620A (ja) * | 2003-01-24 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | 甲状腺受容体におけるシクロアルキル含有アニリドリガンド |
CL2004000545A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul |
US6846836B2 (en) * | 2003-04-18 | 2005-01-25 | Bristol-Myers Squibb Company | N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase |
US7557143B2 (en) | 2003-04-18 | 2009-07-07 | Bristol-Myers Squibb Company | Thyroid receptor ligands |
US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US7256208B2 (en) * | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7388027B2 (en) * | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7696241B2 (en) * | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
US7550499B2 (en) * | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
ATE493973T1 (de) * | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US7145040B2 (en) * | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
US7754755B2 (en) * | 2004-09-23 | 2010-07-13 | Bristol-Myers Squibb Company | Inhibitors of 15-lipoxygenase |
US7429611B2 (en) | 2004-09-23 | 2008-09-30 | Bristol-Myers Squibb Company | Indole inhibitors of 15-lipoxygenase |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
US8143425B2 (en) * | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
US20060128726A1 (en) * | 2004-11-24 | 2006-06-15 | Xuebao Wang | Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations |
US7589088B2 (en) * | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7220859B2 (en) | 2005-01-12 | 2007-05-22 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7314882B2 (en) * | 2005-01-12 | 2008-01-01 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
WO2006076597A1 (fr) * | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Heterocycles bicycliques constituant des modulateurs des recepteurs cannabinoides |
US7459564B2 (en) | 2005-01-13 | 2008-12-02 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor XIa inhibitors |
US20060160850A1 (en) * | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
US7645778B2 (en) * | 2005-01-19 | 2010-01-12 | Bristol-Myers Squibb Company | Heteroaryl compounds as P2Y1 receptor inhibitors |
US7238702B2 (en) * | 2005-02-10 | 2007-07-03 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5HT modulators |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
CN101282991A (zh) * | 2005-05-26 | 2008-10-08 | 布里斯托尔-迈尔斯斯奎布公司 | N-端修饰的胰高血糖素样肽-1受体调节剂 |
US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
US7572808B2 (en) * | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7317012B2 (en) * | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
US20060287342A1 (en) * | 2005-06-17 | 2006-12-21 | Mikkilineni Amarendra B | Triazolopyrimidine heterocycles as cannabinoid receptor modulators |
US7629342B2 (en) * | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
ATE485269T1 (de) * | 2005-06-27 | 2010-11-15 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden |
EP1896417B1 (fr) | 2005-06-27 | 2011-03-23 | Bristol-Myers Squibb Company | Mimetiques lineaires de l'uree antagonistes du recepteur p2y1, utilises dans le traitement des troubles thrombotiques |
US7714002B2 (en) * | 2005-06-27 | 2010-05-11 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
US7728008B2 (en) * | 2005-06-27 | 2010-06-01 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
EP1910361A2 (fr) * | 2005-07-28 | 2008-04-16 | Brystol-Myers Squibb Company | Tetrahydro-1h-pyrido[4,3,b]indoles substitués en tant qu' agonistes et antagonistes du récepteur de sérotonine |
EP1757290A1 (fr) * | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Derivés de triazole comme ligands du recepteur de l'hormone de croissance |
US7534804B2 (en) * | 2005-08-24 | 2009-05-19 | Bristol-Myers Squibb Company | Benzoxazole inhibitors of 15-lipoxygenase |
US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
WO2007027454A1 (fr) * | 2005-08-30 | 2007-03-08 | Bristol-Myers Squibb Company | Composes de dihydropyrimidine heterocycliques |
JP2009506119A (ja) | 2005-08-31 | 2009-02-12 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置 |
AR056155A1 (es) * | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
EP1943215A2 (fr) | 2005-10-31 | 2008-07-16 | Brystol-Myers Squibb Company | Inhibiteurs à base d amide et de bêta-amino de pyrrolidinyle de la dipeptidyl peptidase iv et procédés |
EP1976873A2 (fr) * | 2006-01-11 | 2008-10-08 | Brystol-Myers Squibb Company | Modulateurs de peptides 1 de type glucagon humain et leur utilisation pour traiter le diabète et des états associés |
US7553836B2 (en) * | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
BRPI0709950A2 (pt) * | 2006-04-13 | 2011-08-02 | Actelion Pharmaceuticals Ltd | uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin |
WO2007139589A1 (fr) * | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Modulateurs des récepteurs de glp-1 à libération prolongée |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US20080044326A1 (en) * | 2006-07-04 | 2008-02-21 | Esencia Co., Ltd. | Sterilizer for baby products |
MX2009000385A (es) | 2006-07-12 | 2009-04-06 | Univ Tennessee Res Foundation | Acil-anilidas sustituidas y metodos de uso de las mismas. |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
EA016853B1 (ru) | 2006-08-24 | 2012-08-30 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Замещенные ациланилиды и их применение |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US7960569B2 (en) * | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
WO2008091555A2 (fr) | 2007-01-22 | 2008-07-31 | Gtx, Inc. | Agents se liant aux récepteurs nucléaires |
PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
CN101687873A (zh) | 2007-04-17 | 2010-03-31 | 百时美施贵宝公司 | 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂 |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
MX2009011089A (es) * | 2007-04-23 | 2009-10-30 | Sanofi Aventis | Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12. |
PE20090222A1 (es) | 2007-05-04 | 2009-03-27 | Bristol Myers Squibb Co | Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119 |
ES2388315T3 (es) | 2007-05-04 | 2012-10-11 | Bristol-Myers Squibb Company | Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G |
EP2147008A2 (fr) * | 2007-05-18 | 2010-01-27 | Bristol-Myers Squibb Company | Structures cristallines des inhibiteurs de sglt-2 et procédés pour leur préparation |
US20090011994A1 (en) * | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
PE20090449A1 (es) | 2007-07-17 | 2009-04-18 | Bristol Myers Squibb Co | Agonistas de receptor acoplado a proteina g gpr119 de piridona |
JP2010534722A (ja) * | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
EP2238128B1 (fr) * | 2007-12-26 | 2012-08-22 | Sanofi | Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12 |
PE20091364A1 (es) * | 2008-01-17 | 2009-10-13 | Novartis Ag | Proceso para la preparacion de inhibidores de nep |
EP2103602A1 (fr) | 2008-03-17 | 2009-09-23 | AEterna Zentaris GmbH | Nouveaux dérivés de triazole 1,2,4 et leur processus de fabrication |
US8148363B2 (en) | 2008-05-19 | 2012-04-03 | Schering Corporation | Heterocyclic compounds as factor IXA inhibitors |
PE20091928A1 (es) * | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
WO2010111665A1 (fr) | 2009-03-27 | 2010-09-30 | Bristol-Myers Squibb Company | Procédés destinés à prévenir des événements cardiovasculaires indésirables majeurs par des inhibiteurs de la dpp-iv |
RU2012101214A (ru) | 2009-06-16 | 2013-07-27 | Пфайзер Инк. | Лекарственные формы апиксабана |
TWI393716B (zh) | 2009-08-04 | 2013-04-21 | Merck Sharp & Dohme | 作為ixa因子抑制劑之雜環化合物 |
CA2780941C (fr) | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Formulations pour comprimes a liberation immediate |
HUE040486T2 (hu) | 2009-11-13 | 2019-03-28 | Astrazeneca Ab | Kétrétegû tabletta készítmények |
EP2498757A1 (fr) | 2009-11-13 | 2012-09-19 | Bristol-Myers Squibb Company | Formulations de metformine a masse reduite |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
MX2012011460A (es) | 2010-04-08 | 2012-11-23 | Squibb Bristol Myers Co | Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119. |
US8592396B2 (en) | 2010-04-14 | 2013-11-26 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
MX2012012902A (es) | 2010-05-06 | 2012-12-17 | Bristol Myers Squibb Co | Analogos heteroarilo biciclicos como moduladores de receptor acoplado a la proteina g gpr119. |
US8729084B2 (en) | 2010-05-06 | 2014-05-20 | Bristol-Myers Squibb Company | Benzofuranyl analogues as GPR119 modulators |
KR101476937B1 (ko) | 2010-08-23 | 2014-12-24 | 노파르티스 아게 | Nep 억제제의 제조를 위한 중간체의 제조 방법 |
EP2431035A1 (fr) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Nouveaux dérivés de triazole avec activité de récepteur améliorée et propriétés de biodisponibilité en tant qu'antagonistes de ghréline de récepteurs de secrétagogue d'hormone de croissance |
US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
ES2581323T3 (es) | 2010-12-23 | 2016-09-05 | Purdue Pharma Lp | Formas de dosificación oral sólida resistentes a alteraciones |
TWI631963B (zh) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法 |
CA2853024C (fr) | 2011-11-11 | 2017-08-22 | Pfizer Inc. | 2-thiopyrimidinones |
CA2869587A1 (fr) | 2012-04-06 | 2013-10-10 | Pfizer Inc. | Inhibiteurs de diacylglycerol acyltransferase 2 |
WO2013173198A1 (fr) | 2012-05-16 | 2013-11-21 | Bristol-Myers Squibb Company | Analogues de pyrimidinylpipéridinyloxypyridone en tant que modulateurs de gpr119 |
SI2858987T1 (en) | 2012-06-11 | 2018-06-29 | Bristol-Myers Squibb Company | PREPARATION OF 5-PHENYL-4- (PYRIDIN-2-ILLETHYLAMINO) -CHUINAZOLIN-2-YL) -PIRIDIN-3-SULPHONAMIDE PHOSPHORAMIDIC ACID |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
DK2872482T3 (da) | 2012-07-13 | 2020-09-21 | Oncternal Therapeutics Inc | En fremgangsmåde til behandling af brystkræft med selektiv androgenreceptormodulator (sarm) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
EP2892897A1 (fr) | 2012-09-05 | 2015-07-15 | Bristol-Myers Squibb Company | Antagonistes du récepteur 1 d'hormone concentrant la mélanine de type pyrrolone ou pyrrolidinone |
US9586900B2 (en) | 2012-09-05 | 2017-03-07 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
TR201815850T4 (tr) | 2012-11-14 | 2018-11-21 | Bial Portela & Ca Sa | Pulmoner arteryel hipertansiyonun ve akciğer hasarının tedavisinde kullanım için 1,3-dihidroimidazol-2-tion türevleri. |
NZ707859A (en) | 2012-11-20 | 2019-03-29 | Lexicon Pharmaceuticals Inc | Inhibitors of sodium glucose cotransporter 1 |
US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
EP2970199A1 (fr) | 2013-03-11 | 2016-01-20 | Bristol-Myers Squibb Company | Isoquinolines servant d'inhibiteurs des canaux ioniques potassiques |
ES2616025T3 (es) | 2013-03-11 | 2017-06-09 | Bristol-Myers Squibb Company | Pirrolotriazinas como inhibidores de canales de iones potasio |
CN105008366B (zh) | 2013-03-11 | 2017-11-14 | 百时美施贵宝公司 | 作为钾离子通道抑制剂的吡咯并哒嗪类化合物 |
US9242966B2 (en) | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
JP6348582B2 (ja) | 2013-10-09 | 2018-06-27 | ファイザー・インク | プロスタグランジンep3受容体の拮抗薬 |
WO2015061272A1 (fr) | 2013-10-22 | 2015-04-30 | Bristol-Myers Squibb Company | Inhibiteurs de triazolopyridine 11-bêta hydroxystéroïde déshydrogénase de type 1 à marquage isotopique |
EA032356B1 (ru) | 2014-03-17 | 2019-05-31 | Пфайзер Инк. | Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств |
LT3536685T (lt) | 2014-04-04 | 2022-04-25 | Pfizer Inc. | Biciklinio sulieto heteroarilo arba arilo junginiai ir jų naudojimas kaip irak4 inhibitorių |
US9969724B2 (en) | 2014-04-16 | 2018-05-15 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
KR20160147007A (ko) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체 |
EP3237401B1 (fr) | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonistes de récepteur ep3 de prostaglandine |
EP3292109A1 (fr) | 2015-05-05 | 2018-03-14 | Pfizer Inc | 2-thiopyrimidinones |
EP3303303A1 (fr) | 2015-05-29 | 2018-04-11 | Pfizer Inc | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1 |
CN107787322B (zh) | 2015-06-17 | 2023-07-07 | 辉瑞大药厂 | 三环化合物以及它们作为磷酸二酯酶抑制剂的用途 |
WO2016203335A1 (fr) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet |
CA2995153A1 (fr) | 2015-08-13 | 2017-02-16 | Pfizer Inc. | Composes aryle ou heteroaryle condenses bicycliques |
PT3341367T (pt) | 2015-08-27 | 2021-04-19 | Pfizer | Compostos de arilo ou heteroarilo bicíclicos fusionados como moduladores de irak4 |
WO2017037567A1 (fr) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Régulateurs de la frataxine |
SI3397631T1 (sl) | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
AU2017296338A1 (en) | 2016-07-14 | 2019-01-03 | Pfizer Inc. | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
JP7072557B2 (ja) | 2016-07-22 | 2022-05-20 | ブリストル-マイヤーズ スクイブ カンパニー | グルコキナーゼ活性化剤およびその使用方法 |
AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
MA51203A (fr) | 2017-11-30 | 2020-10-07 | Idorsia Pharmaceuticals Ltd | Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline |
WO2019133445A1 (fr) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1 |
BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
US11254660B2 (en) | 2018-08-31 | 2022-02-22 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
BR112021004839A2 (pt) | 2018-09-26 | 2021-06-08 | Lexicon Pharmaceuticals, Inc. | formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese |
WO2020102575A1 (fr) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Aminothiazoles hétérocycliques et leurs utilisations |
EP3972596A1 (fr) | 2019-05-20 | 2022-03-30 | Pfizer Inc. | Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées |
TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
US20220363673A1 (en) | 2019-06-28 | 2022-11-17 | Pfizer Inc. | 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases |
TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶2 抑制劑 |
EP4094759A1 (fr) | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline |
JP2023512763A (ja) * | 2020-02-06 | 2023-03-29 | パフューズ セラピューティクス, インコーポレイテッド | 眼疾患の処置のための組成物 |
JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
PE20231215A1 (es) | 2020-06-09 | 2023-08-17 | Pfizer | Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos |
US20220023252A1 (en) | 2020-07-27 | 2022-01-27 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
KR20240004643A (ko) * | 2021-04-30 | 2024-01-11 | 퍼퓨즈 세라퓨틱스, 인크. | 안구 질환의 치료를 위한 제약 조성물 및 유리체내 약물 전달 시스템 |
JPWO2022270487A1 (fr) | 2021-06-22 | 2022-12-29 | ||
WO2023275715A1 (fr) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Métabolites de modulateurs sélectifs du récepteur des androgènes |
WO2023026180A1 (fr) | 2021-08-26 | 2023-03-02 | Pfizer Inc. | Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide |
TW202337429A (zh) | 2021-12-01 | 2023-10-01 | 美商輝瑞股份有限公司 | 支鏈酮酸脫氫酶激酶(bckdk)抑制劑及/或降解劑 |
WO2023105387A1 (fr) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Antagonistes du récepteur 4 de la mélanocortine et leurs utilisations |
WO2023144722A1 (fr) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozine destinée à être utilisée dans le traitement du prédiabète ou pour réduire le risque de développer un diabète de type 2 |
WO2023169456A1 (fr) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Agonistes hétérocycliques de glp-1 |
WO2023198140A1 (fr) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Agonistes hétérocycliques de glp-1 |
WO2024075051A1 (fr) | 2022-10-07 | 2024-04-11 | Pfizer Inc. | Inhibiteurs et/ou agents de dégradation de hsd17b13 |
WO2024084360A1 (fr) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Modificateurs de la proteine 3 contenant le domaine phospholipase de type patatine (pnpla3) |
WO2024084390A1 (fr) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Composés pour l'activation de l'ampk |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB804036A (en) * | 1956-03-02 | 1958-11-05 | Hoffmann La Roche | A process for the manufacture of a sulphanilamide of the isoxazole series |
DE1059459B (de) * | 1956-09-04 | 1959-06-18 | Shionogi & Co | Verfahren zur Herstellung des therapeutisch wertvollen 3-Sulfanilamido-5-methylisoxazols |
US2888455A (en) * | 1956-09-04 | 1959-05-26 | Shionogi & Co | New sulfonamide and process for producing the same |
CH364506A (de) * | 1956-09-04 | 1962-09-30 | Shionogi & Co | Verfahren zur Herstellung des therapeutisch wirksamen 3-Sulfanilamido-5-methyl-isoxazols |
GB897440A (en) * | 1960-02-08 | 1962-05-30 | Shionogi & Co | Improvements in or relating to sulfonamides |
GB1473433A (fr) * | 1975-10-09 | 1977-05-11 | Banyu Pharmaceutical Co Ltd Hi | |
US4415496A (en) * | 1981-03-23 | 1983-11-15 | Merck & Co., Inc. | Bicyclic lactams |
DE3276313D1 (en) * | 1981-09-24 | 1987-06-19 | Beecham Wuelfing Gmbh & Co Kg | Sulphonamides |
US4661479A (en) * | 1982-02-19 | 1987-04-28 | Merck And Co., Inc. | Bicyclic lactams as antihypertensives |
EP0194548A3 (fr) * | 1985-03-12 | 1988-08-17 | Dr. Karl Thomae GmbH | Composés sulfonylaminoéthyl, médicament contenant ces composés et leur procédé de préparation |
US5594021A (en) * | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
CA2005741C (fr) * | 1988-12-26 | 1998-06-02 | Hiroyoshi Hidaka | Sulfonoaminoquinolines ayant une activite de relaxation des muscles lisses des vaisseaux |
US5082838A (en) * | 1989-06-21 | 1992-01-21 | Takeda Chemical Industries, Ltd. | Sulfur-containing fused pyrimidine derivatives, their production and use |
PH30484A (en) * | 1990-02-19 | 1997-05-28 | Ciba Geigy | Acy compounds pharmaceutical composition containing said compound and method of use thereof |
WO1991015479A1 (fr) * | 1990-03-30 | 1991-10-17 | Merck & Co., Inc. | Isoxazoles, isothiazoles et pyrazoles substitues |
US5236928A (en) * | 1991-03-19 | 1993-08-17 | Merck & Co., Inc. | Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists |
TW270116B (fr) * | 1991-04-25 | 1996-02-11 | Hoffmann La Roche | |
RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
WO1993008799A1 (fr) * | 1991-11-05 | 1993-05-13 | Smithkline Beecham Corporation | Antagonistes recepteurs de l'endotheline |
SE9103397D0 (sv) * | 1991-11-18 | 1991-11-18 | Kabi Pharmacia Ab | Nya substituerade salicylsyror |
TW224462B (fr) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
US5378715A (en) * | 1992-02-24 | 1995-01-03 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
TW215434B (fr) * | 1992-03-07 | 1993-11-01 | Hoechst Ag | |
NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
AU4376893A (en) * | 1992-05-19 | 1993-12-13 | Immunopharmaceutics, Inc. | Compounds that modulate endothelin activity |
TW287160B (fr) * | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
ES2141197T3 (es) * | 1993-03-19 | 2000-03-16 | Merck & Co Inc | Derivados del acido fenoxifenilacetico. |
EP0626174A3 (fr) * | 1993-04-21 | 1996-01-03 | Takeda Chemical Industries Ltd | Procédé et composition de prophylaxie et/ou traitement de la hypofonction d'organes. |
TW394761B (en) * | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
DK0634175T3 (da) * | 1993-07-15 | 2001-04-30 | Hoffmann La Roche | Farmaceutisk kombination, der indeholder en hæmmer af renin-angiotensin-systemet og en endothelin-antagonist |
US5965732A (en) * | 1993-08-30 | 1999-10-12 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
GB9409618D0 (en) * | 1994-05-13 | 1994-07-06 | Zeneca Ltd | Pyridine derivatives |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
CA2168154A1 (fr) * | 1995-02-06 | 1996-08-07 | Natesan Murugesan | Derives de substitution biphenyliques de sulfonamide, antagonistes de l'endotheline |
DE19509950A1 (de) * | 1995-03-18 | 1996-09-19 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
EE9700251A (et) * | 1995-04-04 | 1998-04-15 | Texas Biotechnology Corporation | Tienüül-, furüül-, pürrolüül- ja bifenüülsulfoonamiidid ning nende derivaadid, mis moduleerivad endoteliini aktiivsust |
UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
-
1998
- 1998-01-23 TW TW087101072A patent/TW536540B/zh active
- 1998-01-26 JP JP53299998A patent/JP2002513397A/ja not_active Ceased
- 1998-01-26 CN CN98802096A patent/CN1117738C/zh not_active Expired - Fee Related
- 1998-01-26 PL PL98334773A patent/PL334773A1/xx unknown
- 1998-01-26 CA CA002279178A patent/CA2279178A1/fr not_active Abandoned
- 1998-01-26 NZ NZ336380A patent/NZ336380A/en unknown
- 1998-01-26 HU HU0001310A patent/HUP0001310A3/hu unknown
- 1998-01-26 IL IL13062298A patent/IL130622A/xx not_active IP Right Cessation
- 1998-01-26 ES ES98906005T patent/ES2205451T3/es not_active Expired - Lifetime
- 1998-01-26 AU AU61349/98A patent/AU730111B2/en not_active Ceased
- 1998-01-26 RU RU99118903/04A patent/RU2183632C2/ru not_active IP Right Cessation
- 1998-01-26 BR BR9807098-3A patent/BR9807098A/pt not_active IP Right Cessation
- 1998-01-26 WO PCT/US1998/001490 patent/WO1998033780A1/fr not_active Application Discontinuation
- 1998-01-26 CZ CZ992362A patent/CZ236299A3/cs unknown
- 1998-01-26 KR KR1019997006831A patent/KR20000070584A/ko not_active Application Discontinuation
- 1998-01-26 EP EP98906005A patent/EP0996618B1/fr not_active Expired - Lifetime
- 1998-01-26 DE DE69819729T patent/DE69819729T2/de not_active Expired - Lifetime
- 1998-01-26 AT AT98906005T patent/ATE254115T1/de active
- 1998-01-27 US US09/013,952 patent/US6043265A/en not_active Expired - Lifetime
- 1998-01-29 ZA ZA9800759A patent/ZA98759B/xx unknown
- 1998-01-30 AR ARP980100427A patent/AR015358A1/es not_active Application Discontinuation
-
1999
- 1999-07-29 NO NO19993691A patent/NO313142B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2205451T3 (es) | 2004-05-01 |
WO1998033780A1 (fr) | 1998-08-06 |
CN1117738C (zh) | 2003-08-13 |
DE69819729T2 (de) | 2004-09-23 |
CA2279178A1 (fr) | 1998-08-06 |
BR9807098A (pt) | 2000-04-18 |
CN1244862A (zh) | 2000-02-16 |
CZ236299A3 (cs) | 1999-11-17 |
IL130622A (en) | 2003-01-12 |
NO993691D0 (no) | 1999-07-29 |
AU730111B2 (en) | 2001-02-22 |
NO993691L (no) | 1999-07-29 |
TW536540B (en) | 2003-06-11 |
JP2002513397A (ja) | 2002-05-08 |
PL334773A1 (en) | 2000-03-13 |
EP0996618A4 (fr) | 2000-05-03 |
ZA98759B (en) | 1999-07-29 |
IL130622A0 (en) | 2000-06-01 |
HUP0001310A3 (en) | 2001-07-30 |
DE69819729D1 (de) | 2003-12-18 |
NZ336380A (en) | 2001-04-27 |
KR20000070584A (ko) | 2000-11-25 |
EP0996618B1 (fr) | 2003-11-12 |
HUP0001310A2 (hu) | 2001-06-28 |
EP0996618A1 (fr) | 2000-05-03 |
ATE254115T1 (de) | 2003-11-15 |
AU6134998A (en) | 1998-08-25 |
AR015358A1 (es) | 2001-05-02 |
RU2183632C2 (ru) | 2002-06-20 |
US6043265A (en) | 2000-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO313142B1 (no) | Endothelin-antagonister: N-[[2'-[[(4,5-dimetyl-3- isoksazolyl)amino]sulfonyl]-4-(2-oksazolyl[[1,1'-bifenyl]-2-yl]metyl]-N,3,3-trimetylbutanamid og N-(4,5-dimetyl-3-isoksazolyl)-2'-[(3,3-dimetyl-2-okso-1-pyrrolidinyl)metyl]-4'-(2-oksazolyl)[1,1'-b | |
US6080774A (en) | Substituted biphenylsulfonamide endothelin antagonists | |
US5514696A (en) | Phenyl sulfonamide endothelin antagonists | |
US5827869A (en) | Substituted biphenyl isoxazole sulfonamides | |
RU2141953C1 (ru) | Сульфамидные соединения или их фармацевтически пригодные соли и способ ингибирования рецепторов ета | |
US5760038A (en) | Substituted biphenyl sulfonamide endothelin antagonists | |
MX2007015422A (es) | Oxadiazoles o isoxazoles policiclicos y su uso como ligandos del receptor de s1p. | |
US5780473A (en) | Substituted biphenyl sulfonamide endothelin antagonists | |
CA2168154A1 (fr) | Derives de substitution biphenyliques de sulfonamide, antagonistes de l'endotheline | |
JP2009539954A (ja) | (trans−4−{4−[({5−[(3,4−ジフルオロフェニル)アミノ]−1,3,4−オキサジアゾール−2−イル}カルボニル)アミノ]フェニル}シクロヘキシル)酢酸の結晶形 | |
US5846985A (en) | Substituted biphenyl isoxazole sulfonamides | |
WO2005009392A2 (fr) | Inhibiteurs de type dihydropyrimidone servant a inhiber l'activite des canaux calciques | |
US5939446A (en) | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists | |
CN102131802A (zh) | 用作凝血酶抑制剂的新型杂环甲酰胺 | |
TWI534142B (zh) | Azole derivatives | |
US6515136B1 (en) | Methods for the preparation of biphenyl isoxazole sulfonamides | |
US5856507A (en) | Methods for the preparation of biphenyl isoxazole sulfonamides | |
US6639082B2 (en) | Methods for the preparation of biphenyl isoxazole sulfonamides | |
US6313308B1 (en) | Methods for the preparation of biphenyl isoxazole sulfonamides | |
WO1997033886A1 (fr) | Sulfonamides de biphenyl isoxazole substitues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |